{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mucosal+Melanoma&page=2", "query": { "condition": "Mucosal Melanoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mucosal+Melanoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T06:48:47.722Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00899496", "title": "Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "immunological diagnostic method", "type": "OTHER" }, { "name": "physiologic testing", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 54, "start_date": "2005-09", "completion_date": "2009-10-23", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-05-22T06:48:47.722Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899496" }, { "nct_id": "NCT07155317", "title": "Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Acral Melanoma", "Advanced Cutaneous Melanoma", "Advanced Mucosal Melanoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Acral Melanoma", "Metastatic Cutaneous Melanoma", "Metastatic Mucosal Melanoma", "Unresectable Acral Melanoma", "Unresectable Cutaneous Melanoma", "Unresectable Mucosal Melanoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2025-10-29", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-05-22T06:48:47.722Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07155317" }, { "nct_id": "NCT01989572", "title": "Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Iris Melanoma", "Medium/Large Size Posterior Uveal Melanoma", "Mucosal Melanoma", "Ocular Melanoma With Extraocular Extension", "Recurrent Melanoma", "Recurrent Uveal Melanoma", "Small Size Posterior Uveal Melanoma", "Stage IIA Cutaneous Melanoma AJCC v6 and v7", "Stage IIA Uveal Melanoma AJCC v7", "Stage IIB Cutaneous Melanoma AJCC v6 and v7", "Stage IIB Uveal Melanoma AJCC v7", "Stage IIC Cutaneous Melanoma AJCC v6 and v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIA Uveal Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIB Uveal Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IIIC Uveal Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Tyrosinase Peptide", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 815, "start_date": "2000-02-23", "completion_date": "2013-01-31", "has_results": true, "last_update_posted_date": "2020-07-07", "last_synced_at": "2026-05-22T06:48:47.722Z", "location_count": 148, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 117 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01989572" }, { "nct_id": "NCT00424515", "title": "Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mucosal Melanoma", "Acral/Lentiginous Melanoma", "Chronically Sun Damaged Melanomas" ], "interventions": [ { "name": "Imatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2006-07", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2016-12-08", "last_synced_at": "2026-05-22T06:48:47.722Z", "location_count": 5, "location_summary": "Denver, Colorado • Tampa, Florida • Chicago, Illinois + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00424515" }, { "nct_id": "NCT00085189", "title": "Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Ciliary Body and Choroid Melanoma, Small Size", "Extraocular Extension Melanoma", "Iris Melanoma", "Metastatic Intraocular Melanoma", "Mucosal Melanoma", "Recurrent Intraocular Melanoma", "Recurrent Melanoma", "Stage IIC Melanoma", "Stage IIIA Intraocular Melanoma", "Stage IIIA Melanoma", "Stage IIIB Intraocular Melanoma", "Stage IIIB Melanoma", "Stage IIIC Intraocular Melanoma", "Stage IIIC Melanoma", "Stage IV Intraocular Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "tyrosinase peptide", "type": "BIOLOGICAL" }, { "name": "recombinant MAGE-3.1 antigen", "type": "BIOLOGICAL" }, { "name": "multi-epitope melanoma peptide vaccine", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "Montanide ISA 51 VG", "type": "DRUG" }, { "name": "agatolimod sodium", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 42, "start_date": "2004-05", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-05-22T06:48:47.722Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085189" }, { "nct_id": "NCT04830124", "title": "Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Mucosal Melanoma" ], "interventions": [ { "name": "Nemvaleukin Alfa Subcutaneous", "type": "DRUG" }, { "name": "Nemvaleukin Alfa Intravenous", "type": "DRUG" }, { "name": "Nemvaleukin Alfa Intravenous Less Frequent Dosing", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mural Oncology, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 173, "start_date": "2021-09-27", "completion_date": "2025-05-08", "has_results": false, "last_update_posted_date": "2025-06-10", "last_synced_at": "2026-05-22T06:48:47.722Z", "location_count": 10, "location_summary": "La Jolla, California • Los Angeles, California • Jacksonville, Florida + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04830124" }, { "nct_id": "NCT03220009", "title": "Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Carcinoma", "Esophageal Carcinoma", "Mucosal Melanoma", "Mucosal Melanoma of the Head and Neck", "Oral Cavity Mucosal Melanoma", "Recurrent Melanoma", "Stage II Vulvar Cancer AJCC v7", "Stage III Vulvar Cancer AJCC v7", "Stage IIIA Vulvar Cancer AJCC v7", "Stage IIIB Vulvar Cancer AJCC v7", "Stage IIIC Vulvar Cancer AJCC v7", "Stage IV Oral Cavity Cancer AJCC v6 and v7", "Stage IV Vulvar Cancer AJCC v7", "Stage IVA Oral Cavity Cancer AJCC v6 and v7", "Stage IVB Oral Cavity Cancer AJCC v6 and v7", "Stage IVC Oral Cavity Cancer AJCC v6 and v7", "Vaginal Carcinoma" ], "interventions": [ { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-11-03", "completion_date": "2021-07-01", "has_results": false, "last_update_posted_date": "2018-10-03", "last_synced_at": "2026-05-22T06:48:47.722Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03220009" }, { "nct_id": "NCT04462406", "title": "Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Melanoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Melanoma of Unknown Primary", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Unresectable Acral Lentiginous Melanoma", "Unresectable Melanoma", "Unresectable Mucosal Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2021-02-09", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-05-22T06:48:47.722Z", "location_count": 482, "location_summary": "Fairhope, Alabama • Mobile, Alabama • Fairbanks, Alaska + 330 more", "locations": [ { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04462406" }, { "nct_id": "NCT04511013", "title": "A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acral Lentiginous Melanoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Cutaneous Melanoma", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Metastatic Mucosal Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2021-01-06", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2025-09-11", "last_synced_at": "2026-05-22T06:48:47.722Z", "location_count": 331, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 234 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04511013" }, { "nct_id": "NCT01961115", "title": "Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mucosal Melanoma", "Recurrent Melanoma", "Recurrent Uveal Melanoma", "Stage IIIA Skin Melanoma", "Stage IIIA Uveal Melanoma", "Stage IIIB Skin Melanoma", "Stage IIIB Uveal Melanoma", "Stage IIIC Skin Melanoma", "Stage IIIC Uveal Melanoma", "Stage IV Skin Melanoma", "Stage IV Uveal Melanoma" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "MELITAC 12.1 Peptide Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2013-09-13", "completion_date": "2017-05-18", "has_results": true, "last_update_posted_date": "2018-06-08", "last_synced_at": "2026-05-22T06:48:47.722Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Durham, North Carolina • Cleveland, Ohio + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01961115" } ] }